Hypertension is one of the most important risk factors for cardiovascular disease. The Global Burden of Disease Study in 2010 described hypertension as the leading risk factor for global disease burden, accounting for 18% of all deaths and 7% of global disabilityadjusted life years.1 Furthermore, hypertension is responsible for 45% of deaths caused by ischemic heart disease and 51% of deaths caused by stroke. As the leading risk for death and disability, hypertension requires a global response. Reducing uncontrolled blood pressure (BP) by 25% is one of nine United Nations targets to reduce noncommunicable diseases (NCDs) by 2025. 3 To that end, hypertension was the feature of World Health Day in 2013.2 The effort to reduce uncontrolled BP is based on two distinct, but integrated, approaches. One is to lower population BP through efforts such as reducing the amount of salt consumed, and the other is to identify people at risk for vascular disease and to clinically manage their hypertension to reduce global cardiovascular risk. 4 The task of clinically managing increased BP globally is daunting. In 2008, 40% of the global population older than 25 years had hypertension, representing approximately 1 billion people. 5 Further, the burden of hypertension is greatest where resources are the lowest. For example, the African region has a hypertension prevalence rate of 46% in adults older than 25 years, compared with the Americas, which have a prevalence rate of 35%. 4 In Haiti, the prevalence rate of hypertension in men and women older than 40 years is 69.1% and 67.2%, respectfully.7 Despite the high burden, awareness, and treatment, control rates are suboptimal in most developing countries, which are disproportionately impacted by hypertension. This also underlines the "know-do gap" in terms of transfer of evidence to policy and practice.Simplistically, the sequential steps to the clinical management of hypertension are: (1) the identification of people whose BP is high; (2) behavioral lifestyle counseling; (3) assessing vascular risk to identify those in whom pharmacologic interventions are cost-effective; (4) prescribing the indicated pharmacologic therapies to reduce vascular risk; and (5) titrating pharmacologic and lifestyle behavior therapy to achieve recommended risk target levels. 8,9 In most low-resource settings (LRS), the current major initial barrier is the identification of people whose BP is high.